Kevin Truong-Balderas

Dr. Kevin Truong-Balderas

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
KTKevin Truong-Balderas
Kevin Truong-Balderas
RCRachel C. Chang
Rachel C. Chang
CLClaudia Lasalle
Claudia Lasalle
YGYi Gao
Yi Gao
NNNicole C. Nowak
Nicole C. Nowak
AMAdrian Pablo Mansini
Adrian Pablo Mansini
Melanoma treatment has been transformed by immune checkpoint blockade, yet many patients still experience primary resistance, limited durability of response, or acquired resistance. These limitations underscore the need for additional targets that reflect melanoma biology while enabling new therapeutic strategies, particularly in biologically defined settings of immune escape such as checkpoint-resistant, HLA-low, dedifferentiated, or stress-adapted melanoma. The B7-H6/NKp30 axis has gained attention as a link between tumor cell stress, immune recognition, and therapy-related adaptation. B7-H6 (NCR3LG1), an inducible ligand for NKp30, has been detected in melanoma cell lines and tumor specimens, and soluble B7-H6 has been identified in a subset of patients. Membrane-bound B7-H6 may support NK-cell activation, whereas ligand shedding and accumulation of soluble B7-H6 may reduce effective antitumor recognition and promote immune evasion. Emerging evidence further suggests that B7-H6 expression may be linked to tumor-intrinsic programs relevant to melanoma cell survival, migration, and adaptation to therapeutic stress. However, B7-H6 is not yet a validated predictive biomarker or an established therapeutic target in melanoma, and current evidence remains limited by small melanoma-specific datasets, incomplete information on spatial and temporal heterogeneity, and the absence of melanoma-focused clinical validation. In this review, we examine the role of the B7-H6/NKp30 axis in immune surveillance, tumor escape, biomarker development, and therapeutic targeting, and discuss its translational potential in melanoma as an emerging but incompletely validated pathway that warrants focused investigation in melanoma states where conventional immune control is limited.

29 September 2026 in Experimental Dermatology
Verified
Journal Article
Closed access
YWYulu Wang
Yulu Wang
KTKevin Truong-Balderas
Kevin Truong-Balderas
YGYi Gao
Yi Gao
CLClaudia Lasalle
Claudia Lasalle
SSSabrina Schundler
Sabrina Schundler
AMAdrian Pablo Mansini
Adrian Pablo Mansini

15 February 2025 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
STSierra Thomas
Sierra Thomas
KTKevin Truong-Balderas
Kevin Truong-Balderas
JMJoseph McGrath
Joseph McGrath
JJJoe Jackson
Joe Jackson
TSTanner Sanberg
Tanner Sanberg
EWErin X. Wei
Erin X. Wei

19 May 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
KTKevin Truong-Balderas
Kevin Truong-Balderas
NNNicole Nowak
Nicole Nowak
PAPaige Adams
Paige Adams
JWJennifer Westrick
Jennifer Westrick
LJLorena Juarez
Lorena Juarez
KAKyle T. Amber
Kyle T. Amber

11 October 2026 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
KTKevin Truong-Balderas
Kevin Truong-Balderas
RCRachel C. Chang
Rachel C. Chang
CLClaudia Lasalle
Claudia Lasalle
MRMeredith Rogers
Meredith Rogers
YWYulu Wang
Yulu Wang
AMAdrian Pablo Mansini
Adrian Pablo Mansini

29 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
KTKevin Truong-Balderas
Kevin Truong-Balderas
RCRachel C. Chang
Rachel C. Chang
CLClaudia Lasalle
Claudia Lasalle
YGYi Gao
Yi Gao
NNNicole C. Nowak
Nicole C. Nowak
AMAdrian Pablo Mansini
Adrian Pablo Mansini
Melanoma treatment has been transformed by immune checkpoint blockade, yet many patients still experience primary resistance, limited durability of response, or acquired resistance. These limitations underscore the need for additional targets that reflect melanoma biology while enabling new therapeutic strategies. The B7-H6/NKp30 axis has gained attention as a link between tumor cell stress, immune recognition, and therapy-related adaptation. B7-H6 (NCR3LG1), an inducible ligand for NKp30, has been detected in melanoma cell lines and tumor specimens, and soluble B7-H6 has been identified in a subset of patients. Membrane-bound B7-H6 may support NK-cell activation, whereas ligand shedding and accumulation of soluble B7-H6 may reduce effective antitumor recognition and promote immune evasion. Emerging evidence further suggests that B7-H6 expression may be linked to tumor-intrinsic programs relevant to melanoma cell survival, migration, and adaptation to therapeutic stress. In this review, we examine the role of the B7-H6/NKp30 axis in immune surveillance, tumor escape, biomarker development, and therapeutic targeting, and discuss its translational potential in melanoma.